GO:0072749 cellular response to cytochalasin B: Cytoskeletal Disruption Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072749 describes any process that changes a cell's state or activity in response to cytochalasin B, a fungal metabolite that disrupts actin polymerization.
• Cytochalasin B triggers rapid cellular responses including DNA fragmentation, multinucleation, and altered secretion, depending on cell type.
• Transformed cells often show differential sensitivity to cytochalasin B compared to normal cells, linking this response to oncogenic signaling.
• Key cellular outcomes include inhibition of cytokinesis leading to multinucleation, disruption of neutrophil functions, and enhanced lymphocyte DNA synthesis.
• Studying this response helps reveal actin-dependent processes in cancer, immune function, and developmental biology.
• CRISPR-based models (knockout, knock-in, overexpression) enable causal testing of genes mediating the cytochalasin B response.
Description
Cytochalasin B is a cell-permeable fungal toxin that binds to the barbed end of actin filaments and inhibits their polymerization, thereby disrupting a wide range of actin-dependent cellular processes. The Gene Ontology term GO:0072749, cellular response to cytochalasin B, captures the collection of cellular changes—morphological, biochemical, and transcriptional—that occur when a cell encounters this compound. This response is not a single pathway but rather a network of downstream events that reflect the cell's attempt to cope with cytoskeletal damage. Researchers study GO:0072749 because it provides a tractable experimental handle on actin cytoskeleton function in diverse contexts, from cell division and motility to secretion and immune cell activation. For example, cytochalasin B treatment leads to multinucleation in cultured mammalian cells due to failed cytokinesis, a phenotype that has been used to probe cell cycle regulation. In neutrophils, cytochalasin B enhances diacylglycerol responses to formyl peptides, revealing links between actin dynamics and signal transduction. In lymphocytes, it can enhance DNA synthesis in response to mevalonic acid, suggesting a role in proliferative signaling. The term is also relevant to cancer biology, as cells transformed by DNA and RNA tumor viruses show differential sensitivity to cytochalasin B, and Rous sarcoma virus transformation alters the response of chicken embryo fibroblasts. Thus, GO:0072749 serves as a focal point for understanding how actin-dependent processes are rewired in disease states.
cellular response to cytochalasin B At A Glance
| GO ID | GO:0072749 |
|---|---|
| GO term | cellular response to cytochalasin B |
| Ontology | biological_process |
| Synonym | none |
| Major function | Mediates cellular changes triggered by cytochalasin B, including actin cytoskeleton disruption, multinucleation, and altered secretion |
| Related cellular components | Actin cytoskeleton, contractile ring, plasma membrane |
| Associated processes | Cytokinesis, cell motility, signal transduction, DNA synthesis |
| Disease relevance | Cancer, immune dysfunction, developmental abnormalities |
What Is GO:0072749?
GO:0072749, cellular response to cytochalasin B, is defined as any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytochalasin B stimulus. This includes immediate cytoskeletal rearrangements, downstream signaling events, and longer-term adaptive or toxic responses.
Why Is cellular response to cytochalasin B Important in Cell Biology?
Understanding cellular response to cytochalasin B is important because it illuminates fundamental actin-dependent processes that are dysregulated in cancer, immune disorders, and developmental diseases. Cytochalasin B is a widely used tool to probe cytoskeletal function, and the cellular response to it reveals how cells sense and react to actin damage. Moreover, differential responses between normal and transformed cells highlight potential therapeutic vulnerabilities.
• Provides a model for studying actin cytoskeleton dynamics and its role in cell division.
• Links cytoskeletal disruption to DNA fragmentation and apoptosis-like events.
• Reveals cell-type-specific responses, such as multinucleation in fibroblasts and enhanced secretion in adrenal tumor cells.
• Highlights how oncogenic transformation alters sensitivity to actin-targeting agents.
• Informs immune cell biology, including neutrophil activation and lymphocyte proliferation.
• Supports drug discovery efforts targeting actin dynamics in cancer and inflammation.
• Enables functional genomics studies using CRISPR screens to identify mediators of the response.
• Helps interpret off-target effects of cytochalasin B in experimental settings.
What Happens During cellular response to cytochalasin B?
Initial Actin Filament Disruption
In simple terms: Cytochalasin B blocks actin filaments from growing, causing them to fall apart.
Cytochalasin B binds to the barbed end of actin filaments, preventing addition of actin monomers and leading to net depolymerization. This rapid disruption of the actin cytoskeleton is the primary trigger for downstream cellular responses.
Cytokinesis Failure and Multinucleation
In simple terms: Cells cannot divide properly and end up with multiple nuclei.
Because the contractile ring required for cytokinesis is actin-based, cytochalasin B treatment causes cytokinesis failure, resulting in multinucleated cells. This phenotype is observed in various cultured mammalian cells and is a hallmark of the cellular response.
DNA Fragmentation and Cell Death
In simple terms: Cytochalasin B can trigger DNA breakage and cell death in some cells.
In certain cell types, cytochalasin B induces DNA fragmentation, a characteristic of apoptosis. This suggests that severe actin disruption can activate cell death pathways.
Altered Secretion and Enzyme Production
In simple terms: Cells change what they secrete and produce in response to the drug.
Cytochalasin B inhibits secretion in adrenal tumor cells stimulated by ACTH, indicating that actin filaments are required for normal secretory processes. Conversely, in neutrophils, it enhances diacylglycerol responses, showing context-dependent effects.
Modulation of Immune Cell Functions
In simple terms: Immune cells like neutrophils and lymphocytes respond differently to the drug.
Cytochalasin B enhances formyl peptide-stimulated diacylglycerol production in neutrophils and boosts mevalonic acid-induced DNA synthesis in lymphocytes. These effects highlight the role of actin dynamics in immune signaling.
Differential Response in Transformed Cells
In simple terms: Cancer cells often react differently to the drug than normal cells.
Cells transformed by DNA and RNA tumor viruses exhibit differential sensitivity to cytochalasin B, and Rous sarcoma virus transformation alters the response of chicken embryo fibroblasts. This suggests that oncogenic pathways modulate the cellular response.
Key Genes Involved in GO:0072749 cellular response to cytochalasin B
The following genes and proteins have been implicated in the cellular response to cytochalasin B, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACTB | Beta-actin, primary target of cytochalasin B | Actin polymerization inhibition |
| ACTG1 | Gamma-actin, component of cytoskeleton | Cytoskeletal disruption |
| PFN1 | Profilin-1, regulates actin polymerization | Modulates response to cytochalasin B |
| COFILIN1 | Actin depolymerization factor | Enhances actin filament turnover |
| ARPC2 | Arp2/3 complex subunit, actin nucleation | Affects cytoskeletal reorganization |
| DIAPH1 | Formin, actin nucleation | Cytokinesis and multinucleation |
| ROCK1 | Rho kinase, regulates actin contractility | Contractile ring formation |
| SRC | Non-receptor tyrosine kinase, oncogene | Transformation alters response |
| RAS | Small GTPase, oncogene | Differential sensitivity in transformed cells |
| MYC | Transcription factor, oncogene | Cell proliferation and DNA synthesis |
| PRKCD | Protein kinase C delta | Neutrophil signaling |
| PLCB1 | Phospholipase C beta 1 | Diacylglycerol production |
| ITGB1 | Integrin beta 1 | Cell adhesion and motility |
| CDK1 | Cyclin-dependent kinase 1 | Cell cycle regulation during multinucleation |
| TP53 | Tumor suppressor p53 | DNA damage response |
| CASP3 | Caspase-3, apoptosis effector | DNA fragmentation |
| NFKB1 | NF-kB subunit, immune signaling | Lymphocyte activation |
How Is cellular response to cytochalasin B Regulated?
The cellular response to cytochalasin B is regulated at multiple levels. Actin-binding proteins such as profilin and cofilin modulate the extent of filament disruption. Signaling pathways involving Rho GTPases and their effectors, like ROCK, influence contractile ring assembly and cytokinesis failure. Oncogenic signaling through SRC and RAS can alter sensitivity to cytochalasin B, as seen in transformed cells. Additionally, immune cell-specific pathways, including formyl peptide receptor signaling, regulate the response in neutrophils.
cellular response to cytochalasin B and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SRC | Cancer (sarcoma) | SRC knockout or point-mutant fibroblasts |
| RAS | Cancer (various) | RAS-overexpressing cell lines |
| ACTB | Developmental actinopathies | ACTB knockout or knock-in cells |
| DIAPH1 | Cytokinesis defects | DIAPH1 knockout HeLa cells |
| PRKCD | Immune dysfunction | PRKCD knockout neutrophils |
Cancer and Oncogenic Transformation
Differential sensitivity to cytochalasin B among cells transformed by DNA and RNA tumor viruses suggests that actin cytoskeleton remodeling is a key feature of oncogenesis. Rous sarcoma virus transformation alters the response of chicken embryo fibroblasts, linking SRC signaling to cytoskeletal changes. These findings imply that the cellular response to cytochalasin B can serve as a readout for oncogenic pathway activity.
Immune Dysfunction and Inflammation
Cytochalasin B enhances neutrophil diacylglycerol responses and lymphocyte DNA synthesis, indicating that actin dynamics are critical for immune cell activation. Dysregulation of these processes may contribute to inflammatory diseases or immunodeficiencies.
Developmental and Cytoskeletal Disorders
Because cytochalasin B disrupts cytokinesis and leads to multinucleation, studying the cellular response can provide insights into developmental disorders caused by cytokinesis defects. Actin cytoskeleton mutations are linked to various developmental syndromes, and cytochalasin B serves as a probe for these pathways.
From cellular response to cytochalasin B-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X mediate cytochalasin B-induced multinucleation? | Knockout of gene X in HeLa or fibroblast cells |
| Does a point mutation in actin alter cytochalasin B sensitivity? | Point-mutant ACTB knock-in cells |
| Does overexpression of oncogene Y change the response? | Overexpression of Y in normal fibroblasts |
| Does tagging of protein Z affect its localization upon cytochalasin B treatment? | Tagged knock-in of Z |
| Which genes are essential for cytochalasin B-induced DNA fragmentation? | CRISPR library screening |
| Does immune cell-specific gene W regulate the response? | Knockout of W in primary neutrophils |
How to Study the cellular response to cytochalasin B Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell imaging | Actin cytoskeleton dynamics | Visualizing filament disruption |
| TUNEL assay | DNA fragmentation | Apoptosis detection |
| RNA-seq | Transcriptional changes | Gene expression profiling |
| Phosphoproteomics | Protein phosphorylation | Signaling pathway analysis |
| CRISPR knockout screen | Gene essentiality | Identifying mediators |
| Multinucleation assay | Cytokinesis failure | Phenotypic screening |
| Neutrophil activation assay | Diacylglycerol production | Immune cell signaling |
Live-Cell Imaging of Actin Dynamics
Fluorescence microscopy with actin markers (e.g., Lifeact-GFP) allows real-time visualization of actin filament disruption upon cytochalasin B treatment. This method reveals morphological changes such as cell rounding and multinucleation.
DNA Fragmentation Assays
TUNEL or comet assays can detect DNA fragmentation induced by cytochalasin B, linking cytoskeletal disruption to apoptosis. These assays are useful for quantifying cell death responses.
Transcriptomics and Proteomics
RNA-seq and mass spectrometry can identify gene expression and protein phosphorylation changes in response to cytochalasin B. Such studies reveal signaling pathways activated downstream of actin disruption.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to cytochalasin B, uncovering novel mediators of the response. This approach is powerful for functional genomics.
How CRISPR Can Be Used to Study GO:0072749 cellular response to cytochalasin B
Knockout
CRISPR knockout of candidate genes such as ACTB or DIAPH1 can test their requirement for cytochalasin B-induced multinucleation. Knockout cells are compared to wild-type for changes in sensitivity.
Point Mutation
Introducing point mutations in actin or associated proteins via CRISPR can reveal specific residues critical for cytochalasin B binding or downstream signaling. Such models help dissect molecular mechanisms.
Knock-in
Knock-in of tagged versions of proteins (e.g., GFP-actin) allows real-time tracking of localization and dynamics during the response. This is valuable for understanding spatiotemporal regulation.
Overexpression
Overexpression of oncogenes like SRC or RAS can mimic transformation and alter the cellular response to cytochalasin B. These models help link oncogenic signaling to cytoskeletal sensitivity.
How EDITGENE Supports cellular response to cytochalasin B Research
Researchers studying cellular response to cytochalasin B-related genes often need to determine whether a candidate gene is causally involved in mediating the cytoskeletal, signaling, or cell death outcomes. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for cellular response to cytochalasin B research.
Frequently Asked Questions About cellular response to cytochalasin B
What is GO:0072749?
GO:0072749 is the Gene Ontology term for cellular response to cytochalasin B, describing any cellular change triggered by this actin-disrupting compound.
What does cytochalasin B do to cells?
Cytochalasin B inhibits actin polymerization, leading to cytoskeletal disruption, multinucleation, and in some cases DNA fragmentation.
What genes are involved in cellular response to cytochalasin B?
Genes encoding actin (ACTB, ACTG1), actin-binding proteins (PFN1, COFILIN1), and signaling molecules (SRC, RAS) are involved.
How is cellular response to cytochalasin B studied?
Common methods include live-cell imaging, DNA fragmentation assays, transcriptomics, and CRISPR screens.
Why do cancer cells respond differently to cytochalasin B?
Oncogenic transformation can alter actin dynamics and signaling, leading to differential sensitivity.
What is the role of actin in cytochalasin B response?
Actin is the direct target; its disruption triggers downstream effects like cytokinesis failure and secretion changes.
Can CRISPR be used to study cytochalasin B response?
Yes, CRISPR knockout, knock-in, and overexpression models enable functional dissection of the response.
What diseases are linked to cytochalasin B response?
Cancer, immune dysfunction, and developmental disorders involving actin cytoskeleton are linked.
How does cytochalasin B affect immune cells?
It enhances neutrophil diacylglycerol responses and lymphocyte DNA synthesis, modulating immune activation.
What are the key cellular outcomes of cytochalasin B treatment?
Multinucleation, DNA fragmentation, altered secretion, and changes in cell motility are key outcomes.
Conclusion
GO:0072749 cellular response to cytochalasin B encompasses a complex network of cellular changes triggered by actin cytoskeleton disruption. From multinucleation to DNA fragmentation and immune modulation, this response provides a valuable window into actin-dependent processes in health and disease. Leveraging CRISPR-based models and multi-omics approaches will continue to uncover the molecular players and pathways involved, offering insights for cancer, immunology, and developmental biology.
References
- 1. O'Neill FJ et al.. 1975. Differential response to cytochalasin B among cells transformed by DNA and RNA tumor viruses.. J Natl Cancer Inst 55(4):951-5 PMID: 171432
- 2. Kolber MA et al.. 1990. Cytochalasin B induces cellular DNA fragmentation.. FASEB J 4(12):3021-7 PMID: 2394319
- 3. Mrotek JJ et al.. 1977. Response of adrenal tumor cells to adrenocorticotropin: site of inhibition by cytochalasin B.. Biochemistry 16(14):3177-81 PMID: 196628
- 4. Croop J et al.. 1975. Response of myogenic and fibrogenic cells to cytochalasin B and to colcemid. I. Light microscope observations.. J Cell Biol 65(2):271-85 PMID: 1092700
- 5. Menko AS et al.. 1982. The response of chicken embryo dermal fibroblasts to cytochalasin B is altered by Rous sarcoma virus-induced cell transformation.. Mol Cell Biol 2(3):320-30 PMID: 6287234
- 6. Honeycutt PJ et al.. 1986. Cytochalasin B enhancement of the diacylglycerol response in formyl peptide-stimulated neutrophils.. J Biol Chem 261(34):15900-5 PMID: 3782096
- 7. Larson RA et al.. 1983. Neutrophil-assisted DNA synthesis by human lymphocytes in response to mevalonic acid; enhancement by cytochalasin B.. Cell Immunol 81(2):357-72 PMID: 6640672
- 8. Takii M et al.. 1976. Differential response of cultured mammalian cells to cytochalasin B in multinucleation.. Jpn J Exp Med 46(2):95-100 PMID: 933370
